Phenex Pharmaceuticals AG (Phenex) today announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH). GS-9674 is a novel, synthetic and non-steroidal FXR agonist which was originally developed by Phenex and then sold to Gilead. In December 2014, Gilead acquired the Farnesoid X Receptor (FXR) program from Phenex, in a deal valued at 470 million USD. GS-9674 is the clinical drug candidate that Gilead has elected to test in patients with liver diseases such as NASH, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Company News: Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge
– Final panel demonstrates overall weighted average sensitivity of 91.4% and overall weighted average specificity of 99.5% across all lower respiratory tract panel pathogens
– Unyvero results available after approximately five hours only, compared to three to four days on average for microbiology culture based methods
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration for its Unyvero Platform and the Unyvero LRT Lower Respiratory Tract Cartridge.
Company News: Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections; Presents at Key Investor and Scientific Conferences in Q1, 2017
– Highly multiplexed panel covers up to 112 diagnostic targets
– Third new panel developed within one year after IPO
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the completion of development of its fourth Application Cartridge.